Last updated on January 2010

A Phase II Study Of Gliadel Concomitant Temozolomide And Radiation Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma


Brief description of study

To determine the safety and efficacy of surgical resection with Gliadel® 3.85% wafer implantation, followed by concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide and bevacizumab in subjects undergoing initial surgery for newly-diagnosed high grade glioma.

Clinical Study Identifier: NCT00660621

Find a site near you

Start Over

Kentuckiana Cancer Institute

Louisville, KY United States
  Connect »